[EXEL] Exelixis, Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Commercial Physical & Biological Resarch

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 15.41 Change: 0.47 (3.15%)
Ext. hours: 15.31 Change: -0.1 (-0.65%)

chart EXEL

Refresh chart

Strongest Trends Summary For EXEL

EXEL is in the medium-term up 39% in 1 year. In the long-term up 459% in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Exelixis, Inc., a biotechnology company, develops small molecule therapies for the treatment of cancer in the United States. The company focuses primarily on developing and commercializing COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive and metastatic medullary thyroid cancer. It is also evaluating COMETRIQ in two ongoing Phase III pivotal trials for metastatic castration-resistant prostate cancer; an Phase III pivotal trial for metastatic renal cell cancer; and an Phase III pivotal trial for advanced hepatocellular cancer. In addition, the company develops cobimetinib, an inhibitor of MEK, which is in Phase III clinical trial evaluating the combination of cobimetinib with vemurafenib versus vemurafenib. Exelixis, Inc. has collaborations with Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Phar

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 43.07% Sales Growth - Q/Q27.68% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-80.97% ROE156.1% ROI-102.16%
Current Ratio2.13 Quick Ratio2.09 Long Term Debt/Equity5.49 Debt Ratio-0.4
Gross Margin91.55% Operating Margin-615.77% Net Profit Margin-774.12% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-220 K Cash From Investing Activities49.9 M Cash From Operating Activities-45.09 M Gross Profit8.62 M
Net Profit-35.17 M Operating Profit-22.76 M Total Assets282.93 M Total Current Assets125.04 M
Total Current Liabilities58.68 M Total Debt368.43 M Total Liabilities429.69 M Total Revenue9.39 M
Technical Data
High 52 week29.78 Low 52 week13.65 Last close22.37 Last change3.95%
RSI42.86 Average true range0.95 Beta1.53 Volume4.05 M
Simple moving average 20 days0.6% Simple moving average 50 days3.34% Simple moving average 200 days13.82%
Performance Data
Performance Week0.49% Performance Month-1.19% Performance Quart26.6% Performance Half23.32%
Performance Year-23.13% Performance Year-to-date13.73% Volatility daily2.27% Volatility weekly5.07%
Volatility monthly10.4% Volatility yearly36.03% Relative Volume263.48% Average Volume4.26 M
New High New Low


2019-06-10 08:07:52 | See what the IHS Markit Score report has to say about Exelixis Inc.

2019-06-07 06:00:00 | Exelixis Bets on Breakthroughs in Oncology

2019-06-06 13:55:00 | Top 5 Stocks in the Fight Against Cancer

2019-06-04 08:06:40 | See what the IHS Markit Score report has to say about Exelixis Inc.

2019-05-31 09:31:01 | Why Is Exelixis EXEL Down 1% Since Last Earnings Report?

2019-05-30 15:09:37 | Is Exelixis, Inc.'s NASDAQ:EXEL CEO Being Overpaid?

2019-05-29 16:05:00 | Exelixis Announces Webcasts of Investor Conference Presentations in June 2019

2019-05-24 08:25:12 | Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics

2019-05-22 09:37:01 | Merck to Buy Private Cancer Drugmaker Peloton Therapeutics

2019-05-16 08:00:00 | Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program

2019-05-15 09:27:01 | Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer

2019-05-14 16:05:00 | Exelixis Announces Webcasts of Investor Conference Presentations on May 21, 2019

2019-05-14 07:49:00 | These 3 Value Stocks Are Absurdly Cheap Right Now

2019-05-13 06:00:00 | Exelixis’ Collaborator Daiichi Sankyo Launches MINNEBRO® Esaxerenone Tablets in Japan

2019-05-10 07:32:02 | Jim Cramer Weighs In On Zebra Technologies, Exelixis And More

2019-05-07 09:00:00 | Where Will Gilead Sciences Spend Its Cash?

2019-05-07 08:06:41 | See what the IHS Markit Score report has to say about Exelixis Inc.

2019-05-06 15:31:00 | Exelixis Expands Its Sales

2019-05-06 13:08:48 | Estimating The Fair Value Of Exelixis, Inc. NASDAQ:EXEL

2019-05-02 11:21:03 | Exelixis EXEL Earnings & Revenues Beat Estimates in Q1

2019-05-02 02:51:33 | Exelixis Inc EXEL Q1 2019 Earnings Call Transcript

2019-05-02 01:20:55 | Edited Transcript of EXEL earnings conference call or presentation 1-May-19 9:00pm GMT

2019-05-01 18:35:10 | Exelixis EXEL Beats Q1 Earnings and Revenue Estimates

2019-05-01 17:27:50 | Exelixis: 1Q Earnings Snapshot

2019-05-01 16:06:00 | Exelixis Initiating Phase 3 Pivotal Trial COSMIC-313 of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma

2019-05-01 16:05:00 | Exelixis Announces First Quarter 2019 Financial Results and Provides Corporate Update

2019-05-01 07:39:56 | The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

2019-04-30 09:04:35 | Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO?

2019-04-29 09:17:00 | 2 Incredibly Cheap Value Stocks to Buy Now

2019-04-26 09:43:00 | News Surrounds 3 Small Biotechs, With a Merger Claiming One

2019-04-25 09:42:01 | Exelixis EXEL to Report Q1 Earnings: What's in Store?

2019-04-25 06:30:00 | Exelixis’ Partner Takeda Announces Filing of New Drug Application in Japan for CABOMETYX® Cabozantinib for Advanced Renal Cell Carcinoma

2019-04-24 10:33:02 | Analysts Estimate Exelixis EXEL to Report a Decline in Earnings: What to Look Out for

2019-04-23 15:54:00 | Kidney-Cancer Market: Good for Patients, Hard for Investors

2019-04-21 17:54:52 | Did Hedge Funds Drop The Ball On Exelixis, Inc. EXEL ?

2019-04-20 08:00:00 | 3 Cancer Treatment Stocks to Buy in April

2019-04-19 14:12:00 | 5 Top Pharmaceutical Stocks to Buy in 2019

2019-04-17 16:05:00 | Exelixis to Release First Quarter 2019 Financial Results on Wednesday, May 1, 2019

2019-04-16 19:26:11 | ProQR Initiates Dosing in Phase II/III Eye Disorder Study

2019-04-15 14:18:38 | Has Exelixis, Inc. NASDAQ:EXEL Got Enough Cash?

2019-04-11 06:33:06 | Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock

2019-04-09 10:51:13 | See what the IHS Markit Score report has to say about Exelixis Inc.

2019-04-05 22:03:02 | Exelixis EXEL Rallies 22.4% YTD: What to Expect Ahead?

2019-04-05 16:05:00 | Exelixis to Present at the 18th Annual Needham Healthcare Conference on April 10, 2019

2019-04-01 09:25:01 | The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage

2019-03-28 08:06:37 | See what the IHS Markit Score report has to say about Exelixis Inc.

2019-03-27 10:02:07 | Market Trends Toward New Normal in 3M, Exelixis, Wright Medical Group N.V, MSA Safety Incorporated, Principal Financial Group, and Portland General Electric — Emerging Consolidated Expectations, Analyst Ratings

2019-03-26 08:26:32 | See what the IHS Markit Score report has to say about Exelixis Inc.

2019-03-18 14:26:28 | Morgan Stanley Drops Bearish Exelixis Stance, Sees 'Limited Downside Risk'

2019-03-18 13:06:50 | Signal Says Buy Options Insurance on This Biotech